Free Trial

Gelteq (GELS) Competitors

Gelteq logo
$1.91 +0.04 (+2.14%)
As of 07/25/2025 04:00 PM Eastern

GELS vs. CUE, OTLK, RPTX, INMB, QNTM, IKNA, VRCA, ICCC, HOWL, and MNOV

Should you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Cue Biopharma (CUE), Oncobiologics (OTLK), Repare Therapeutics (RPTX), INmune Bio (INMB), Quantum Biopharma (QNTM), Ikena Oncology (IKNA), Verrica Pharmaceuticals (VRCA), ImmuCell (ICCC), Werewolf Therapeutics (HOWL), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry.

Gelteq vs. Its Competitors

Gelteq (NASDAQ:GELS) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Gelteq has higher earnings, but lower revenue than Cue Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GelteqN/AN/A-$2.33MN/AN/A
Cue Biopharma$9.29M7.16-$40.67M-$0.67-1.32

Gelteq has a net margin of 0.00% compared to Cue Biopharma's net margin of -507.87%. Gelteq's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
GelteqN/A N/A N/A
Cue Biopharma -507.87%-228.43%-114.66%

Cue Biopharma has a consensus price target of $4.00, indicating a potential upside of 353.05%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Gelteq.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gelteq
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cue Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Gelteq and Gelteq both had 1 articles in the media. Cue Biopharma's average media sentiment score of 1.87 beat Gelteq's score of 0.94 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Gelteq Positive
Cue Biopharma Very Positive

35.0% of Cue Biopharma shares are held by institutional investors. 10.8% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cue Biopharma beats Gelteq on 7 of the 11 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GELS vs. The Competition

MetricGelteqMED IndustryMedical SectorNASDAQ Exchange
Market Cap$17.65M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E RatioN/A21.1828.1020.05
Price / SalesN/A286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book1.478.378.665.87
Net Income-$2.33M-$55.19M$3.25B$258.55M
7 Day Performance4.95%5.88%4.22%3.73%
1 Month Performance1.60%17.33%10.51%11.75%
1 Year PerformanceN/A4.42%34.40%18.03%

Gelteq Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GELS
Gelteq
N/A$1.91
+2.1%
N/AN/A$17.65MN/A0.00N/A
CUE
Cue Biopharma
4.0437 of 5 stars
$0.91
+1.7%
$3.00
+231.5%
+25.5%$68.19M$9.29M-1.3560Positive News
OTLK
Oncobiologics
2.2591 of 5 stars
$2.02
-2.9%
$9.60
+375.2%
-75.5%$67.98MN/A-2.2320News Coverage
RPTX
Repare Therapeutics
2.6591 of 5 stars
$1.56
+2.0%
$4.50
+188.5%
-60.0%$66.48M$53.48M-0.51180Positive News
INMB
INmune Bio
2.3077 of 5 stars
$2.83
-1.0%
$18.40
+549.9%
-68.0%$66.38M$10K-1.4610Positive News
Upcoming Earnings
QNTM
Quantum Biopharma
N/A$22.41
-1.0%
N/AN/A$65.10MN/A-1.40N/A
IKNA
Ikena Oncology
2.827 of 5 stars
$1.34
-2.9%
$3.00
+123.9%
-14.9%$64.91M$9.16M-1.5670News Coverage
Positive News
Earnings Report
Analyst Forecast
Stock Split
VRCA
Verrica Pharmaceuticals
3.9464 of 5 stars
$0.69
-1.8%
$8.00
+1,056.1%
-8.8%$64.37M$7.57M-0.5840Positive News
Gap Down
ICCC
ImmuCell
0.3111 of 5 stars
$7.01
+0.9%
N/A+58.9%$63.41M$26.49M-100.1970
HOWL
Werewolf Therapeutics
4.0485 of 5 stars
$1.38
-0.7%
$8.33
+503.9%
-50.4%$61.92M$1.88M-0.8340
MNOV
MediciNova
1.607 of 5 stars
$1.27
+0.4%
$7.00
+453.4%
+12.3%$61.80MN/A-5.4810News Coverage
Analyst Forecast
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:GELS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners